IMARC Group, a leading market research company, has recently releases report titled “Cancer Immunotherapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global cancer immunotherapy market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
How big is the cancer immunotherapy market?
The global cancer immunotherapy market size reached US$ 106.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 182.0 Billion by 2028, exhibiting a growth rate (CAGR) of 8.8% during 2023-2028.
Cancer is a disease starting in any tissue or organ of the body on account of the abnormal cell growth that invades the adjoining parts and spreads to other organs. Cancer immunotherapy is a treatment that improves the ability of the immune system in fighting this disease. It is utilized in treating several types of cancers, including melanoma, breast, colorectal, prostate, head and neck, lung, etc. Cancer immunotherapy works by activating immune system by triggering a response capable of destroying the cancer cells. As a result, it finds extensive applications in hospitals, cancer research centers, clinics, etc., across countries.
Request Free Sample Copy of This Report: https://www.imarcgroup.com/cancer-immunotherapy-market/requestsample
What are the growth prospects and trends in the cancer immunotherapy industry?
The escalating number of cancer patients across the globe is among the primary factors driving the cancer immunotherapy market. Besides this, the elevating utilization of monoclonal antibodies to treat various types of cancer by selectively attacking cancerous cells is further augmenting the market growth.
Apart from this, the rising prevalence of multiple myeloma and melanoma is also catalyzing the global market. Moreover, the introduction of various patient assistance programs that offer financial assistance to low-income individuals to cater to drug coverage is acting as another significant growth-inducing factor.
Furthermore, the development of advanced treatment variants with improved efficacy and the continuous technological advancements in clinical therapies are expected to bolster the cancer immunotherapy market in the coming years.
What is included in market segmentation?
The report has segmented the market into the following categories:
Breakup by Therapy Type:
- Monoclonal Antibodies
- Cancer Vaccines
- Checkpoint Inhibitors
- Immunomodulators
- Others
Breakup by Application:
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head and Neck Cancer
- Others
Breakup by End User:
- Hospitals
- Cancer Research Centers
- Clinics
- Others
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Who are the key players operating in the industry?
The report covers the major market players including:
Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson Johnson, Merck KGAA, Novartis AG, Pfizer Inc., Sanofi, and Seagen Inc.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: sales@imarcgroup.com
Follow us on Twitter: @imarcglobal
LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/
